Q-omics provides the consensus-scored MIR6807 profile across patient tissues and cancer cell-line models. MIR6807 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, MIR6807 is differentially expressed in 4, with the highest sampling consensus in UCEC. Additionally, MIR6807 RNA expression shows 5,473 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight BRCA, UCEC, and KIRC as cancer lineages where MIR6807 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR6807 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR6807 survival associations across molecular data types. MIR6807 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR6807 RNA expression–survival associations across cancer types. High MIR6807 expression shows unfavorable associations in BRCA, OV, MESO, THYM, COAD and STAD. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for MIR6807 RNA expression.
This table summarizes MIR6807 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR6807. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR6807 shows higher tumor expression in UCEC, COAD, HNSC and LUSC. The UCEC box plot shows higher MIR6807 RNA expression in tumor versus normal tissue (log2 FC = +0.760, t-test p < 0.001).
This table shows molecular features associated with MIR6807 in patient tissues and cancer cell lines. In patient samples, MIR6807 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
